Evidence map›Paper›PMID 27830374›Full record

ArticleWorld journal of urology2017

Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study.

Mohammad Abufaraj, Marco Moschini, Francesco Soria, Kilian Gust, Mehmet Özsoy, Romain Mathieu, Morgan Rouprêt, Vitaly Margulis, Jose A Karam, Christopher G Wood and 4 more

Open access · hybridAbstract read
In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications.International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 4 countries.

Mohammad AbufarajDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Marco MoschiniDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Francesco SoriaDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Kilian GustDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Mehmet ÖzsoyDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Romain MathieuDepartment of Urology, University of Rennes, Rennes, France.
Morgan RouprêtDepartment of Urology, Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris, France.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jose A KaramDepartment of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Christopher G WoodDepartment of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Alberto BrigantiDepartment of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy.
Karim BensalahDepartment of Urology, University of Rennes, Rennes, France.
Andrea HaitelDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Shahrokh F ShariatDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. sfshariat@gmail.com.
Vienna General Hospital · ATCentre Hospitalier Universitaire de Rennes · FRThe University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · USVita-Salute San Raffaele University · ITMedical University of Vienna · ATSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the role of N-cadherin as prognostic biomarker in patients with upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients. PATIENTS AND

methodsImmunohistochemistry was used to evaluate the status of N-cadherin expression in 678 patients with unilateral sporadic UTUC treated with radical nephroureterectomy. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected. The Kaplan-Meier method was used to estimate recurrence-free survival, overall survival and cancer-specific survival. Disease recurrence, overall mortality and cancer-specific mortality probabilities were tested in Cox regression models.

resultsExpression of N-cadherin was observed in 292 (43.1%) of patients, and it was associated with advanced tumour stage (p < 0.04), lymph node metastases (p = 0.04) and sessile architecture (p < 0.02). Within a median follow-up of 37.5 months (IQR 20-66), 171 patients (25.2%) experienced disease recurrence and 150 (22.1%) died from UTUC. In univariable analyses, N-cadherin expression was significantly associated with higher probability of recurrence (p = 0.01), but not overall (p = 0.9) or cancer-specific mortality (p = 0.06). When adjusted for the effects of all available confounders, N-cadherin was not associated with any of the survival outcomes.

conclusionN-cadherin is expressed in approximately 2/5 of UTUs. It is associated with adverse pathologic factors but not with survival outcomes. Its clinical value remains limited.

Indexed as

CarcinomaKidney NeoplasmsNephroureterectomyUreteral NeoplasmsAgedBiomarkers, TumorCadherinsFemaleHumansImmunohistochemistryKaplan-Meier EstimateKidneyMaleNeoplasm StagingPredictive Value of TestsPrognosisBiomarkers, TumorCadherinsN-CadherinPredictionSurvivalUpper tract urothelial carcinomaUrothelial carcinomaUTUC prognosis

Identifiers

PMID27830374
PMCPMC5486535
OpenAlexW2555498424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.